Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Status Recruiting

Clinical Trial Summary

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas.

Clinical Trial Description

Effective treatment for recurrent gliomas is still challenging. Malignant gliomas are considered to be one of the most angiogenic cancers and are mostly sustained by vascular endothelial growth factor (VEGF) signaling via its endothelial tyrosine kinase receptor VEGF receptor 2 (VEGFR-2). Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits VEGFR-2. Apatinib has been demonstrated as monotherapy that prolongs OS in patients with gastric cancers after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse effects. This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study also seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas. The creation of a registry for patients with recurrent gliomas treated by Apatinib with detailed survival data, radiological data, histopathology image data and with sufficient sample size for artificial intelligence provides opportunities for personalized prediction of responses to Apatinib. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04216550
Study type	Observational [Patient Registry]
Source	The First Affiliated Hospital of Zhengzhou University
Contact	Zhenyu Zhang, Dr.
Phone	+86 17839973727
Email	fcczhangzy1@zzu.edu.cn
Status	Recruiting
Phase
Start date	January 1, 2018
Completion date	June 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03233204` - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Phase 2
Recruiting	`NCT05045027` - Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma	Early Phase 1
Not yet recruiting	`NCT04562077` - Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
Active, not recruiting	`NCT05611645` - Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence	Phase 2
Completed	`NCT04089449` - A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas	Phase 1
Active, not recruiting	`NCT03213678` - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Active, not recruiting	`NCT03698994` - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Active, not recruiting	`NCT03213665` - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Terminated	`NCT01324635` - Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors	Phase 1
Recruiting	`NCT05406700` - Niraparib In Recurrent IDH 1/2 Gliomas	Early Phase 1
Recruiting	`NCT05660369` - CARv3-TEAM-E T Cells in Glioblastoma	Phase 1
Recruiting	`NCT03796273` - Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases	Early Phase 1
Terminated	`NCT05297864` - PARP Inhibition for Gliomas (PI-4G or π4g)	Phase 2
Completed	`NCT01580969` - Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma	Phase 1/Phase 2
Recruiting	`NCT03155620` - Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Phase 2
Recruiting	`NCT04943718` - Personalized Vaccine for Patients With Recurrent Malignant Glioma	Phase 1
Active, not recruiting	`NCT04164901` - Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	Phase 3
Active, not recruiting	`NCT03212274` - Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	Phase 2
Recruiting	`NCT04740190` - Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd	Phase 2
Recruiting	`NCT03411408` - Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.	N/A